NaV1.7 Patch-Clamp Screening Platform
We provide NaV1.7 patch-clamp screening using an in-house stable cell line for analgesic drug discovery, ion channel pharmacology and lead-compound screening. The platform centers on gold-standard manual patch clamp, emphasizing data accuracy, consistent channel performance and interpretable results to support candidate-compound activity assessment and mechanistic evaluation.
Stable Cell Expression and Manual Patch Clamp for Reliable NaV1.7 Data
NaV1.7 is a voltage-gated sodium channel of substantial interest in pain-related drug discovery. Cell-line expression stability, channel-current quality, assay window and data reproducibility all influence how reliably candidate compounds can be evaluated and how efficiently a project can progress.
Our in-house NaV1.7 stable cell line is combined with manual patch-clamp recording to support accurate current measurements, clear assessment of pharmacological responses and robust validation data. Applications include lead discovery, molecular optimization, activity confirmation and mechanistic studies.
In-House Stable Cell Line
The platform uses an internally developed NaV1.7 stable cell line, with an emphasis on stable expression, a well-characterized cellular background and batch consistency for sustained screening and project validation.
Current Quality and Assay Consistency
Optimization focuses on current amplitude, seal quality, assay-window stability and reproducibility to support high-quality NaV1.7 pharmacology data.
Gold-Standard Manual Patch Clamp
Compared with relying solely on an automated platform, manual patch clamp is particularly suited to detailed examination of current characteristics, drug-blocking effects and complex channel behavior, and provides an important reference method for validation.
Screening and Confirmation
The platform supports initial candidate screening, hit confirmation, structure-activity relationship comparisons, concentration-response testing and validation at critical project milestones.
Core Services
- NaV1.7 candidate-compound activity screening and preliminary prioritization.
- Concentration-response testing and IC50 evaluation.
- Hit confirmation and comparative validation of samples from different batches.
- Analysis of channel-current block characteristics, effect magnitude and pharmacological trends.
- Study results aligned with project milestones to support internal decisions, external collaborations and submission packages.
Why Recording Quality Matters in NaV1.7 Studies
Screening results for NaV1.7, a prominent analgesic target, can directly affect compound progression and development priorities. Unstable cell-line performance, a narrow assay window or variable recording conditions can bias candidate assessment and subsequent resource allocation.
Combining an in-house stable cell line with detailed manual patch-clamp measurements helps improve data confidence and reduce the risk of false-positive and false-negative findings. This approach supports confirmation of important compounds and in-depth studies at key project milestones.
Platform Quality and Data Value
The NaV1.7 screening workflow emphasizes recording quality and depth of validation. Beyond establishing an in-house stable cell line, ongoing optimization addresses experimental success rate, current quality, recording stability and reproducibility to support functional screening and confirmation for this high-value target.
NaV1.7 Screening Validation Data
The in-house stable cell line and gold-standard manual patch-clamp workflow support stable, clearly resolved and reproducible NaV1.7 current recordings.
Block curves, concentration-response relationships and batch-consistency data provide evidence for candidate screening, activity confirmation and validation at critical project stages.
